Endra Life Sciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary

ENDRA Life Sciences

14/08/2026 22:17

ENDRA Life Sciences Inc NDRA.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.71.  The lone analyst forecast for the quarter was for a loss of 84 cents per share. 
Reported revenue was zero​; analysts expected zero. 
ENDRA Life Sciences Inc's reported EPS for the quarter was 6 cents​.
The company reported quarterly net income of $160 thousand.
ENDRA Life Sciences Inc shares had fallen by 16.1% this quarter and lost 1.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 26.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $25.00, about 82.1% above its last closing price of $4.47
This summary was machine generated from LSEG data August 14 at 09:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.84
0.06
Beat
Mar. 31 2026 
-1.23
-1.80
Missed
Dec. 31 2025 
-1.23
-3.26
Missed
Sep. 30 2025 
-1.95
-2.10
Missed